Clinical

Dataset Information

0

Physiotherapy Prehabilitation for cancer surgery patients.


ABSTRACT: Interventions: Participants will participate in an initial assessment conducted by a senior physiotherapist to determine baseline exercise tolerance and other descriptors. This includes a 6 minute walking test (6MWT) and a balance/frailty assessment called a short physical performance battery (SPPB). A quality of life survey (QLQ C30) will also be assessed at this time. They will then participate in a 2x weekly, one hour in length duration tailored supervised exercise program. This is conducted by a senior physiotherapist and 4th year physiotherapy students from Curtin University. Participants recruited may be currently receiving neoadjuvant chemoradiotherapy (CRT), have finished CRT on not completing CRT. The intervention is carried out despite their current CRT as to not impact on their cancer care. It has already been proven that exercise is safe at any point within the patients’ treatment journey and this is why this approach was taken. The program will consist of a walking program (determined from their 6MWT result) and resistance exercises via standard gymnasium equipment. The program is run as a group class, with a maximum of 10 participants per class. Their program will be documented and progressed / regressed as deemed appropriate by the supervising physiotherapist. The participants will be asked to exercise at a ‘moderate intensity’ which is described as ‘difficulty walking and talking’. The walking program is implemented on a flat walking track within the hospital, and resistance exercises are completed on standard gymnasium equipment in the Physiotherapy gym. These include, upper limb exercise with free weights, sit to stand, step ups, calf raises, body weight push up, large muscle group exercise on gym equipment (leg press, latissimus Primary outcome(s): Exercise tolerance in meters, assessed using 6-minute walk test (6MWT) [Following completion of a 6 week Prehabilitation exercise program compared to pre-completion of the program] Study Design: Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy

DISEASE(S): Sarcoma,Cancer-pancreatic,Complex Bowel Cancer,Cancer-sarcoma (also See 'bone')-soft Tissue,Elective Upper Abdominal Surgery,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon),Cancer-oesophageal (gullet),Cancer,Upper Gastrointestinal Cancer

PROVIDER: 2472407 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2465036 | ecrin-mdr-crc
2007-06-07 | E-MEXP-740 | biostudies-arrayexpress
| 2460946 | ecrin-mdr-crc
2020-01-05 | GSE140629 | GEO
| 2603510 | ecrin-mdr-crc
| 2470295 | ecrin-mdr-crc
| 2460284 | ecrin-mdr-crc
2016-12-14 | MTBLS164 | MetaboLights
| 18233 | ecrin-mdr-crc
2017-06-09 | GSE76503 | GEO